1 – 10 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers : an international cohort study
(
- Contribution to journal › Article
- 2020
-
Mark
Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers : Results from the BRCA1 and BRCA2 cohort consortium
(
- Contribution to journal › Article
- 2018
-
Mark
Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility
(
- Contribution to journal › Article
- 2016
-
Mark
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
(
- Contribution to journal › Article
-
Mark
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer
(
- Contribution to journal › Article
-
Mark
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
2016) In Nature Genetics(
- Contribution to journal › Article
-
Mark
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
(
- Contribution to journal › Article
-
Mark
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
(
- Contribution to journal › Article
- 2015
-
Mark
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.
(
- Contribution to journal › Article
-
Mark
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.
(
- Contribution to journal › Article